Cripto-1 Overexpression May Increase Risk of Bladder Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Tumor Biology, researchers have found Cripto-1, an embryonic gene, overexpression may play role in the development of bladder cancer and may have value as a possible prognostic biomarker in patients with bladder cancer.
For the study, researchers sought to investigate the significance of Cripto-1 expression in patients with bladder cancer. To do so, the researchers compared tissue samples of cancerous bladders and noncancerous bladders. They found that Cripto-1 was overexpressed in bladder cancer tissue samples and greatly linked with tumor size (P = 0.003) and tumor grade (P = 0.001).
Furthermore, Cripto-1 overexpression was significantly linked with SRY-related HMG-box gene 2 expression (P = 0.003) and Ki-67 (P = 0.001). SRY-related HMG-box gene 2 regulates gene expression in the stomach and Ki-67 is strongly associated with cell proliferation.
In addition, bladder cancer samples with high Cripto-1 levels were more likely associated with decreased recurrence/metastasis-free survival compared with samples with low Cripto-1 levels (P = 0.011). Statistical analyses demonstrated that Cripto-1 may be a prognostic marker for recurrence/metastasis-free survival (P = 0.036).
Cripto-1 gene overexpression may play role in the development of bladder cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer